Hillsdale Investment Management Inc. purchased a new stake in Bristol-Myers Squibb Company (NYSE:BMY) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 5,840 shares of the biopharmaceutical company’s stock, valued at approximately $326,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Tradewinds Capital Management LLC lifted its stake in Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares in the last quarter. Proficio Capital Partners LLC lifted its stake in Bristol-Myers Squibb by 29.6% during the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 504 shares in the last quarter. American National Bank lifted its stake in Bristol-Myers Squibb by 11.7% during the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 225 shares in the last quarter. Blue Chip Partners Inc. lifted its stake in Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares in the last quarter. Finally, Heritage Trust Co purchased a new stake in Bristol-Myers Squibb during the first quarter valued at about $123,000. 69.82% of the stock is owned by institutional investors.

In related news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.23% of the company’s stock.

BMY has been the subject of a number of analyst reports. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Cowen set a $65.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, August 14th. Credit Suisse Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Wednesday, August 16th. Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price objective for the company in a research note on Thursday, August 17th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $66.00 price objective (up from $63.00) on shares of Bristol-Myers Squibb in a research note on Thursday, August 24th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $64.93.

Bristol-Myers Squibb Company (NYSE BMY) opened at $62.42 on Friday. The firm has a market capitalization of $101,213.53, a PE ratio of 20.89, a PEG ratio of 2.34 and a beta of 1.18. Bristol-Myers Squibb Company has a twelve month low of $46.01 and a twelve month high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the prior year, the company posted $0.77 EPS. The company’s quarterly revenue was up 6.7% on a year-over-year basis. sell-side analysts forecast that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be issued a $0.40 dividend. The ex-dividend date is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.56%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is currently 61.42%.

COPYRIGHT VIOLATION WARNING: “Hillsdale Investment Management Inc. Takes $326,000 Position in Bristol-Myers Squibb Company (BMY)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/09/hillsdale-investment-management-inc-takes-326000-position-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.